Display options
Cite
Hyde J, Benbrook DM. Sensitivities of Uterine Adenocarcinoma, Mixed Mullerian Tumor (MMT) and Sarcoma Cell Lines to Chemotherapeutic Agents and a Flex-Het Drug. Am J Pharmacol Toxicol. 2006;1(4):83-86doi: 10.3844/ajptsp.2006.83.86.
Hyde, J., & Benbrook, D. M. (2006). Sensitivities of Uterine Adenocarcinoma, Mixed Mullerian Tumor (MMT) and Sarcoma Cell Lines to Chemotherapeutic Agents and a Flex-Het Drug. American journal of pharmacology and toxicology, 1(4), 83-86. https://doi.org/10.3844/ajptsp.2006.83.86
Hyde, Johnny, and Benbrook, Doris M. "Sensitivities of Uterine Adenocarcinoma, Mixed Mullerian Tumor (MMT) and Sarcoma Cell Lines to Chemotherapeutic Agents and a Flex-Het Drug." American journal of pharmacology and toxicology vol. 1,4 (2006): 83-86. doi: https://doi.org/10.3844/ajptsp.2006.83.86
Hyde J, Benbrook DM. Sensitivities of Uterine Adenocarcinoma, Mixed Mullerian Tumor (MMT) and Sarcoma Cell Lines to Chemotherapeutic Agents and a Flex-Het Drug. Am J Pharmacol Toxicol. 2006 Jan 01;1(4):83-86. doi: 10.3844/ajptsp.2006.83.86. PMID: 19890461; PMCID: PMC2772184.
Copy Download .nbib Format: NLM
Share it on

Am J Pharmacol Toxicol. 2006 Jan 01;1(4):83-86. doi: 10.3844/ajptsp.2006.83.86.

Sensitivities of Uterine Adenocarcinoma, Mixed Mullerian Tumor (MMT) and Sarcoma Cell Lines to Chemotherapeutic Agents and a Flex-Het Drug.

American journal of pharmacology and toxicology

Johnny Hyde, Doris M Benbrook

Affiliations

  1. Department of Obstetrics and Gynecology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73190.

PMID: 19890461 PMCID: PMC2772184 DOI: 10.3844/ajptsp.2006.83.86

Abstract

The administration and combination of a variety of chemotherapeutic agents for treatment of advanced or recurrent uterine cancer of different histologies is under current debate. Mixed Mullerian Tumors (MMTs), which contain both adenocarcinoma and sarcoma components, are the most rate histologic type and it is therefore difficult to conduct clinical trials to determine if they should be treated like endometrial adenocarinomas or like sarcomas. Flexible Heteroarotionoids (Flex-Hets) are a promising class of anti-cancer drugs with low toxicity that have demonstrated activity against a wide variety of cancer types, but their efficacy in uterine cancers is unknown. The objective of this study was to determine if cell lines established from endometrial carcinoma (HEC-1-A), uterine sarcoma (SK-UT-1) and MMT (MES-SA) cancers exhibit differential sensitivities to cisplatin, carboplatin, paclitaxel, docetaxel, doxorubicin and SHetA2, if SHetA2 can enhance sensitivity to the chemotherapeutic drugs and if SHetA2 exhibits a differential effect on uterine cancer cells in comparison to normal endometrial cells using a cytotoxicity assay. These cell lines did not differ in their sensitivities to platinum or taxel drugs. Doxorubicin was active against the sarcoma but not the adenocarcinoma or MMT cell lines. SHetA2 decreased the survival of all three cell lines, but did not enhance their sensitivities to the chemotherapeutic agents. Two of the three uterine cancer cell lines were more sensitive to SHetA2 in comparison to normal endometrial cells. In conclusion, doxorubicin appears to have a greater effect against sarcoma than other uterine histology types. SHetA2 is affective against uterine cancer cell lines, but does not enhance their sensitivities to chemotherapeutic agents.

References

  1. J Med Chem. 2004 Feb 12;47(4):999-1007 - PubMed
  2. Invest New Drugs. 2005 Oct;23(5):417-28 - PubMed
  3. Eur J Cancer. 2002 Jul;38(11):1437-46 - PubMed
  4. Ann Oncol. 2004 Aug;15(8):1173-8 - PubMed
  5. Cancer Res. 2003 Jul 1;63(13):3826-32 - PubMed
  6. J Natl Cancer Inst. 2001 Apr 4;93(7):516-25 - PubMed
  7. Curr Opin Obstet Gynecol. 2004 Feb;16(1):1-4 - PubMed
  8. Fertil Steril. 2002 Sep;78(3):596-602 - PubMed
  9. Cancer Chemother Pharmacol. 2006 Nov;58(5):561-9 - PubMed
  10. Gynecol Oncol. 2005 May;97(2):624-37 - PubMed
  11. J Clin Oncol. 2004 Jun 1;22(11):2159-66 - PubMed
  12. Int J Gynecol Cancer. 2002 Nov-Dec;12(6):687-90 - PubMed
  13. J Clin Oncol. 2004 Oct 1;22(19):3902-8 - PubMed
  14. Am J Clin Oncol. 2005 Jun;28(3):295-300 - PubMed
  15. Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7135-40 - PubMed

Publication Types

Grant support